

### Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Presently Amended) An adhesive preparation for percutaneous absorption comprising dissolving such an amount of norethisterone that can exist in a base without crystallization in the absence of hexylene glycol into a base of the adhesive preparation which contains a styrene-isoprene-styrene block copolymer, and estradiol in an amount not more than 2 % by weight based on the whole base.

2. (Presently Amended) The adhesive preparation for percutaneous absorption according to claim 1, wherein norethisterone is dissolved in the amount showing the releasing rate in water being not less than 30% after 25 hours determined by the drug releasing test according to the cylinder method described in the USP Drug release ~~724~~ Test under the following conditions:

Test solution	900 ml water;
---------------	---------------

Temperature of test solution  $32.0 \pm 0.5^{\circ}\text{C}$ ;

Distance from the lowest end of cylinder to the basal inner plane of vessel  $25 \pm 2$  mm; and

Revolution of cylinder 50 rpm.

3. (Original) The adhesive preparation for percutaneous absorption according to any of claims 1 – 2, wherein an amount of norethisterone to be dissolved is in the amount not more than 2 % by weight based on the whole base.

4. (Cancelled).

5. (Presently Amended) The adhesive preparation for percutaneous absorption according to any of ~~claims 1-4~~claims 1 - 2, wherein the adhesive preparation containing a styrene-isoprene-styrene block copolymer comprises 10 – 30 % by weight of a styrene-isoprene-styrene

M. Maki, et al.  
U.S.S.N.: 10/030,015  
Page 3

block copolymer, 10 – 60 % by weight of a softener and 20 – 60 % by weight of an adhesive resin based on the whole base.